Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 934-941

  Davidoff, Amy J ^a,b   Gardner, James F ^b   Seal, Brian ^c   Edelman, Martin J ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c SANOFI   (France)

Author keywords

Geriatric; Lung cancer; Performance status; SEER

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; HUMAN; LOCALLY ADVANCED NON SMALL CELL LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 79955485075     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820eed00     Document Type: Article

References (34)

1. Ries LAG, Melbert D, Krapcho M, et al. (Eds.). SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, 2007. Available at: http://seer.cancer.gov/csr/1975-2005/. Accessed December 10, 2008.
2. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945. (Pubitemid 20332333)
3. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-smallcell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
4. Edelman MJ, Gandara DR, Roach M 3rd, et al. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg 1996; 61:1564-1572. (Pubitemid 26151395)
5. Curran WJ, Scott C, Langer G, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer. Initial report of RTOG 9410. Proc Am Soc Clin Oncol 2000;19:484a.
6. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699. (Pubitemid 29415225)
7. Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704. (Pubitemid 46797950)
8. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
9. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621a (abstract 2499).
10. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-smallcell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
11. Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005;23:3760-3767.
12. Sause W, Kolesar P, Taylor SV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364. (Pubitemid 30111583)
13. Potosky AL, Saxman S, Wallace RB, et al. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004;22: 3261-3268. (Pubitemid 41103681)
14. Shugarman LR, Mack K, Sorbero ME, et al. Race and sex differences in the receipt of timely and appropriate lung cancer treatment. Med Care 2009;47:774-781.
15. Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-4978. (Pubitemid 46638623)
16. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEERMedicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:IV-3-18.
17. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383. (Pubitemid 17055592)
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
20. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191-2197.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd Ed. Hoboken, NJ: John Wiley and Sons, 2002.
22. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: John Wiley and Sons, 1999.
23. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-2960. (Pubitemid 39200133)
24. Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 1996;143:1059-1068. (Pubitemid 26140334)
25. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-1482.
26. Langer C, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group 94-10. Proc Am Soc Clin Oncol 2002;21:299a.
27. Jeremic B, Shibamoto Y. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer 1995;13:21-30.
28. Socinski MA, Zhang C, Herndon JE 2nd, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004;15:1033-1041. (Pubitemid 39089779)
29. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009;20:98-102.
30. Stinchcombe TE, Hodgson L, Herndon JE 2nd, et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 2009;4:1117-1125.
31. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002;40:IV-26-35.
32. Davidoff AJ, Rapp T, Onukwugha E, et al. Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care 2009;47:1229-1236.
33. Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc 2009;57:1403-1410.
34. Davidoff AJ, Zuckerman IH, Pandya NB, et al. Development of a performance status prediction model for use in administrative data analyses. J Clin Oncol 2010;28(Suppl):15s (abstract 6006).